Special Issue

Advanced Nanocarriers for Targeted Drug Delivery in Inflammation-Associated Diseases

Message from the Guest Editors

Chronic inflammation is a defining feature of many debilitating diseases, including autoimmune disorders, infectious diseases, neurodegenerative conditions, and cancer. The complexity of the inflammatory microenvironment and the presence of biological barriers present significant challenges to effective treatment. In recent years, however, advanced nanocarrier systems have emerged as a powerful tool for overcoming these limitations by enabling precise drug delivery to inflamed tissues while minimizing systemic side effects.

This Special Issue aims to showcase the latest developments in the design, characterization and application of nanocarriers engineered for targeted drug delivery in inflammation-associated diseases. The emphasis will be on innovative strategies to improve selectivity, enhance pharmacokinetics and enable controlled drug release in response to inflammatory signals. Examples include polymeric nanoparticles, liposomes, dendrimers, micelles and stimuli-responsive systems that exploit the unique pathophysiological features of inflamed tissues.

Guest Editors

Dr. Ana Laura López-Machado

Institute of Materials and Nanotechnology, University of La Laguna, Tenerife, Spain

Dr. Rossella Laurano

Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Turin, Italy

Deadline for manuscript submissions

31 March 2026



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/255424

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

